[EN] COMBINATION OF AN ANTI-CANCER AGENT SUCH AS A TYROSINEKINASE INHIBITOR AND A STAT5 ANTAGONIST, PREFERABLY A THIAZOLIDINEDIONE, FOR ELIMINATING HEMATOLOGIC CANCER STEM CELLS IN VIVO AND FOR PREVENTING HEMATOLOGIC CANCER RELAPSE<br/>[FR] ASSOCIATION D'UN AGENT ANTICANCÉREUX TEL QU'UN INHIBITEUR DE LA TYROSINE KINASE ET UN ANTAGONISTE DE STAT5, DE PRÉFÉRENCE UN THIAZOLIDINEDIONE, POUR ÉLIMINER LES CELLULES SOUCHES DES CANCERS HÉMATOLOGIQUES IN VIVO ET POUR PRÉVENIR DES RECHUTES DES CANCERS HÉMATOLOGIQUES
申请人:COMMISSARIAT ENERGIE ATOMIQUE
公开号:WO2014068397A1
公开(公告)日:2014-05-08
Provided are methods for eliminating hematologic cancer stem cells in vivo, and thus preventing cancer relapse. The methods comprise a Signal Transducer and Activator of Transcription 5 (STAT5) antagonist (e.g., a PPARy agonist) after the patient has had ana initial course of treatment with an anti-cancer agent (e.g., a TKI), to eliminate residual cancer stem cells which cause relapse.